The invention provides quinazoline-7-ether derivatives, particularly 4-anilinyl-6-butenamido-quinazoline-7-ether derivatives that are inhibitors of the receptor protein tyrosine kinases (RTK). The compounds are useful in the treatment of diseases and disorders where RTK activity is implicated such as a hyperproliferative diseases (e.g., cancer). Also provided are methods of preparation of the quinazoline derivatives and methods of use as therapeutic agents alone or in a drug combination.本發明提供喹唑啉-7-醚衍生物,特定而言4-苯胺基-6-丁烯醯胺基-喹唑啉-7-醚衍生物,其係受體蛋白質酪胺酸激酶(RTK)之抑制劑。該等化合物可用於治療涉及RTK活性之疾病及病症,例如過度增殖性疾病(例如癌症)。本發明亦提供製備該等喹唑啉衍生物之方法及單獨或以藥物組合作為治療劑之使用方法。